Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Next Previous
X
Search
Trial Profile

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBI 1901 (Primary) ; VBI 1901 (Primary) ; AS01B; Carmustine; Granulocyte macrophage colony stimulating factor; Lomustine
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man
  • Sponsors VBI Vaccines

    • Most Recent Events

    • 04 Jun 2024 Based on part 1 results the study was amended into a randomized study.
    • 04 Jun 2024 Trial design of phase IIb (As of January 31st 2024 , n=12 ) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2024 According to VBI vaccine media release, data of this trial will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top